Beam

The Hartford Enhances Employee Benefits For Small Businesses Through New Relationship With Beam Benefits

Retrieved on: 
Tuesday, August 29, 2023
Insurance, Human Resources, Optical, Health, Small Business, Professional Services, Health Insurance, Dental, The Hartford, Beam, Small business, Access, Health insurance, Management

The Hartford , a leading provider of employee benefits and small business insurance, is enhancing its benefit options for small businesses with dental and vision plans through a new relationship with Beam Benefits.

Key Points: 
  • The Hartford , a leading provider of employee benefits and small business insurance, is enhancing its benefit options for small businesses with dental and vision plans through a new relationship with Beam Benefits.
  • Brokers can integrate dental and vision benefits with The Hartford’s group income protection (also known as disability) and life insurance to develop competitive benefits packages for small employers with fewer than 100 employees.
  • Beam Disability provided by The Hartford will be available for quoting in early September in five states, with additional states to follow.
  • Raftery, Frommeyer, and Chris Nordstrom, national sales director for small business in Group Benefits at The Hartford, will discuss the changing benefits landscape and highlight the features of the dental and vision benefits.

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Well, Tissue, ESCAPE, Research and development, HBF, Biotechnology, Allele, Gene editing, SCD, Clinical trial, Cancer, SMART Process Acceleration Development Environment, G&A, CD34, BCL11A, AATD, Fetal hemoglobin, CGMP, Patient, Investment, Security (finance), Administration, Cas9, Hematology, Sickle cell disease, Liver, Growth, Hospital, Trial of the century, LNP, LNP Media Group, R, Services General Administration and Coordination Department, Government of Sindh, Treatment, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Television, Beam

CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported second quarter 2023 financial results and provided an update on its clinical and pipeline progress.

Key Points: 
  • Beam continues to expect initiation of current good manufacturing practice compliant operations at its North Carolina manufacturing facility in late 2023.
  • Research & Development (R&D) Expenses: R&D expenses were $97.6 million for the second quarter of 2023, compared to $74.6 million for the second quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $24.7 million for the second quarter of 2023, compared to $24.1 million for the second quarter of 2022.
  • Net Loss: Net loss was $82.8 million for the second quarter of 2023, or $1.08 per share, compared to $72.0 million for the second quarter of 2022, or $1.02 per share.

Beam Suntory Announces CEO Transition

Retrieved on: 
Tuesday, July 18, 2023
Retail, Restaurant, Bar, Other Retail, Wine & Spirits, Heart, University, Senior, Kraft Foods, Marketing, Culture, Baladi, Senior advisor, Business, Hughes, Suntory, Procter, MBA, COVID, Kellogg School, Beam, Procter & Gamble, GM, Beam Suntory, Humble Oil, Growth, Family, Northwestern University, Management

Beam Suntory President & CEO Albert Baladi today announced that he will transition CEO responsibilities effective October 1, 2023, to Greg Hughes, the company’s current Senior Vice President Chief Growth & Brands Officer.

Key Points: 
  • Beam Suntory President & CEO Albert Baladi today announced that he will transition CEO responsibilities effective October 1, 2023, to Greg Hughes, the company’s current Senior Vice President Chief Growth & Brands Officer.
  • Baladi has served on the executive leadership team of Beam Suntory for 12 years, including the past five years as President & CEO.
  • Since he stepped into the CEO role in 2019, Beam Suntory’s annual sales have grown at high single digits to more than $5 billion.
  • I am very proud of what we have built these past 12 years and am grateful for the opportunity to lead Beam Suntory as President & CEO during a five-year period of massive transformation for our company.”
    “On behalf of Suntory Holdings, I’d like to express deep appreciation to Albert for his tremendous leadership, exemplary contributions, and impact during his 12-year tenure with Beam Suntory,” said Tak Niinami, President & CEO of Suntory Holdings.

Beam Global Executes Binding LOI to Acquire Europe Based Amiga, Announces Pricing of Upsized $22.5 Million Public Offering of Common Stock and Announces Q2 Revenue and Unit Guidance

Retrieved on: 
Tuesday, June 20, 2023
Letter, Beam, EV, Q3, Acquisition, Beam Suntory, Engineering, Retail, Life insurance, Amiga

Additionally, Beam Global today announced the pricing of an upsized underwritten public offering, as previously announced, of 2,500,000 shares of its common stock at a public offering price of $9.00 per share.

Key Points: 
  • Additionally, Beam Global today announced the pricing of an upsized underwritten public offering, as previously announced, of 2,500,000 shares of its common stock at a public offering price of $9.00 per share.
  • Gross proceeds from the offering are expected to be approximately $22.5 million before deducting underwriting discounts, commissions and estimated offering expenses.
  • Beam Global has granted the underwriters a 45-day option to purchase up to an additional 375,000 shares of common stock.
  • The offering is expected to close on or about June 22, 2023, subject to the satisfaction of customary closing conditions.

Beam Global Executes Binding LOI to Acquire Europe Based Amiga, Announces Proposed Public Offering of Common Stock and Announces Q2 Revenue and Unit Guidance

Retrieved on: 
Friday, June 16, 2023
Letter, EV, Q3, Beam Suntory, Prospectus, Beam, Acquisition, Engineering, Clothing, Retail, Amiga

SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- Beam Global, (Nasdaq: BEEM, BEEMW) (“Beam Global” or the “Company”), a leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, today announced the execution of a binding Letter of Intent to acquire European based Amiga DOO Kraljevo (“Amiga”), an established manufacturer of specialized structures and equipment, producing street lights, communications and energy infrastructure whose manufacturing, engineering and sales teams serve municipalities, states and commercial customers in 16 nations. The transaction is pending completion of Beam Global’s due diligence, which will include customary closing conditions, and is expected to be finalized in Q3 or Q4 2023.

Key Points: 
  • The transaction is pending completion of Beam Global’s due diligence, which will include customary closing conditions, and is expected to be finalized in Q3 or Q4 2023.
  • Additionally, Beam Global today announced that it has commenced an underwritten public offering of shares of its common stock.
  • The offering is not conditioned on the completion of the potential acquisition of Amiga.
  • Maxim Group LLC and Freedom Capital Markets are acting as joint book-runners of the proposed offering.

Genome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical Trial

Retrieved on: 
Thursday, May 25, 2023
Oxygen, Infection, SCD, Clinical trial, Research, Cell, DSM-IV codes, Pain, Genetic counseling, S, Sickle, Fetal hemoglobin, Patient, SAN, Blood, Anemia, Sickle cell disease, Death, Disease, Pharmaceutical industry, Medical imaging, Vaccine, Beam

SOUTH SAN FRANCISCO, Calif., May 25, 2023 /PRNewswire/ -- Genome Medical , the leading telehealth provider of genetic services and solutions, is teaming up with Beam Therapeutics Inc. to provide access to genetic counseling for participants in Beam's BEACON clinical trial evaluating BEAM-101 as a potential treatment for sickle cell disease (SCD).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 25, 2023 /PRNewswire/ -- Genome Medical , the leading telehealth provider of genetic services and solutions, is teaming up with Beam Therapeutics Inc. to provide access to genetic counseling for participants in Beam's BEACON clinical trial evaluating BEAM-101 as a potential treatment for sickle cell disease (SCD).
  • Through Genome Medical, Beam is sponsoring genetic counseling to provide educational resources and support to its BEACON clinical trial participants as they navigate the complexities that arise from their sickle cell diagnosis and clinical trial journey.
  • Beam will not receive any identifiable information about the patients who elect to pursue genetic counseling with Genome Medical.
  • Sickle cell disease is a group of genetic disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body.

Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, RBC Capital Markets, Conference, Pharmaceutical industry, Self storage, Beam

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2023 Global Healthcare Conference on Wednesday, May 17, 2023, at 11:00 a.m.

Key Points: 
  • CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2023 Global Healthcare Conference on Wednesday, May 17, 2023, at 11:00 a.m.
  • ET in NYC.
  • A live webcast will be available in the investor section of the company's website at www.beamtx.com , and will be archived for 60 days following the presentation.

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
Well, GMP, Tissue, ESCAPE, Research and development, Drug development, Stargardt disease, Hematology, Gene targeting, Biotechnology, SCD, Clinical trial, Bone marrow, Cancer, G&A, Patient, Eye, Science, AATD, Investment, Security (finance), Administration, DSM-IV codes, Sickle cell disease, Liver, R, LNP, LNP Media Group, Services General Administration and Coordination Department, Government of Sindh, Society, Vaccine, Pharmaceutical industry, Medical imaging, Stargardt, Beam

CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2023 financial results and provided an update on its BEACON clinical trial and pipeline progress.

Key Points: 
  • Beam expects to fully enroll the sentinel cohort in 2023.
  • Beam expects to initiate current good manufacturing practice compliant operations at its North Carolina manufacturing facility in late 2023.
  • Research & Development (R&D) Expenses: R&D expenses were $99.6 million for the first quarter of 2023, compared to $65.4 million for the first quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $23.5 million for the first quarter of 2023, compared to $19.2 million for the first quarter of 2022.

JIM BEAM® LAUNCHES NEW GLOBAL BRAND CAMPAIGN: PEOPLE ARE GOOD FOR YOU

Retrieved on: 
Monday, May 1, 2023
Diamond, DNA, Advertising, Jim Beam, Beam, Partnership, Good for You, Friends, BISU Visual Identity, Véronique

CLERMONT, Ky., May 1, 2023 /PRNewswire/ -- Jim Beam, the world's number one bourbon and enduring American icon, announces the launch of its new global brand campaign to celebrate the notion that "People Are Good For You." The campaign, which includes a new website and advertising, accompanied by the rollout of a new visual identity and packaging, kicks off the brand's strategy to reinvigorate and drive an emotional connection between Jim Beam and the next generation of consumers. 

Key Points: 
  • CLERMONT, Ky., May 1, 2023 /PRNewswire/ -- Jim Beam, the world's number one bourbon and enduring American icon, announces the launch of its new global brand campaign to celebrate the notion that "People Are Good For You."
  • "We started this process by going back to our heritage as a brand crafted through the generations by the first family of bourbon," says Jim Beam Global Brand Vice President Veronique Mura.
  • Our new global brand campaign puts our authenticity and warmth on full display and reminds audiences that there's no feeling more special than being around other people."
  • Honoring the DNA of the brand, the refreshed visual identity started with an exploration of Jim Beam through the generations.

Ansible Labs, the payments company bridging crypto and the traditional economy, has partnered with Zero Hash to facilitate a seamless crypto off-ramp

Retrieved on: 
Tuesday, April 18, 2023
Ansible, Beam, Hash, Money transmitter, USD, Partnership, Commerce, Cryptocurrency

Beam leverages Zero Hash’s API infrastructure to offer a frictionless, secure & rapid solution for consumers and businesses to convert their crypto to cash.

Key Points: 
  • Beam leverages Zero Hash’s API infrastructure to offer a frictionless, secure & rapid solution for consumers and businesses to convert their crypto to cash.
  • Zero Hash abstracts away the back-end complexities of custody, liquidity, and settlement to enable Beam users to convert crypto assets into USD and receive payouts directly to their preferred bank account.
  • Zero Hash has built the industry’s default infrastructure for companies like Ansible Labs who need stable, secure, and trusted partners to facilitate seamless crypto off-ramp.
  • “We are pleased that Ansible Labs have selected Zero Hash to provide the end-to-end crypto rails to power their seamless crypto off-ramp experience,” said Edward Woodford, CEO and Founder of Zero Hash.